Trending...
- ApostilleDepot.com Expands Services to Offer Comprehensive Apostille & Document Legalization Solutions in Massachusetts and New Hampshire
- "Army of Liars" Exposes How Social Media Profits from Disinformation
- SafeTea Launches App to Safeguard Women
BOSTON, Aug. 6, 2024 ~ Dotmatics, a leading provider of R&D scientific software, has announced a significant minority investment in BioGlyph, a startup biotech software company. This investment is aimed at supporting the development of technology that will visually illustrate, register, and model biologic molecules, with a specific focus on multispecific antibodies (MsAbs).
BioGlyph is known for its proprietary technology and exceptional talent in the field of MsAbs research and development. The company's expertise lies in accelerating and improving the development of protein therapeutics. With MsAbs being one of the fastest growing research modalities today, Dotmatics' investment in BioGlyph is a strategic move to support its customers who are pursuing new therapies using a multimodal approach to life science discovery.
MsAbs have the ability to bind two or more antigens, opening up new possibilities for therapeutic applications that traditional monoclonal antibodies cannot fulfill. This technology is crucial for bridging different cells or receptor proteins on the same cell, presenting groundbreaking opportunities in therapeutic development.
More on Boston Chron
According to Dotmatics CEO Thomas Swalla, this investment aligns with the growing demand from customers for software that supports MsAb formats. As drug discovery becomes more multidisciplinary, there is a need for advanced software that can keep up with new modalities. This led Dotmatics to introduce their new scientific intelligence platform, Luma, which allows scientists to connect old and new science in a way that enhances the precision and efficiency of antibody design and production.
BioGlyph is led by CEO and co-founder Fernando Garces, who previously served as director of Protein Therapeutics at Gilead Sciences and principal scientist at Amgen. The company's founder McClain Kressman is currently pursuing a PhD at the University of California, Santa Cruz. Avi Peltz also serves as a co-founder and leads software development at BioGlyph.
Garces explains that after 20 years in protein engineering, he recognized the limitations of traditional tools in keeping up with the increasing complexities of biotherapeutics, especially MsAbs. This led the BioGlyph team to develop a visual software solution that empowers protein engineers with creativity while managing registration, data labeling, and in-silico testing of MsAbs' fitness, among other functions. He believes that their software will empower R&D scientists to make better decisions that accelerate timelines and lower costs.
More on Boston Chron
Kressman adds that working together with Dotmatics will help them bring this highly sought-after technology to market in an expedited manner. He also mentions their eagerness to harness the power of AI in life sciences and provide protein engineers with cutting-edge tools for the future.
However, it is important to note that this press release contains forward-looking statements and is intended for informational purposes only. It should not be relied upon for making purchase decisions as it does not guarantee any specific functionality or product release. The development, release, and timing of any products or capabilities remain at the sole discretion of Dotmatics.
Additionally, no representation or warranty is provided regarding the accuracy or reliability of the information expressed in this press release. Any legal effect will only be applicable if stated in one or more definitive agreements involving both parties.
BioGlyph is known for its proprietary technology and exceptional talent in the field of MsAbs research and development. The company's expertise lies in accelerating and improving the development of protein therapeutics. With MsAbs being one of the fastest growing research modalities today, Dotmatics' investment in BioGlyph is a strategic move to support its customers who are pursuing new therapies using a multimodal approach to life science discovery.
MsAbs have the ability to bind two or more antigens, opening up new possibilities for therapeutic applications that traditional monoclonal antibodies cannot fulfill. This technology is crucial for bridging different cells or receptor proteins on the same cell, presenting groundbreaking opportunities in therapeutic development.
More on Boston Chron
- Inframark Announces New Chief Financial Officer
- Hayloft Big Creek Now Pre-Leasing
- Jeanne Penn joins Cambridge Healthcare Research as Vice President, US Commercial for Solici
- Green Office Partner Ranked #1 on Crain's 2024 List of Best Places to Work in Chicago
- Peak Physical Therapy & Sports Performance Participates in"Go Baby Go"
According to Dotmatics CEO Thomas Swalla, this investment aligns with the growing demand from customers for software that supports MsAb formats. As drug discovery becomes more multidisciplinary, there is a need for advanced software that can keep up with new modalities. This led Dotmatics to introduce their new scientific intelligence platform, Luma, which allows scientists to connect old and new science in a way that enhances the precision and efficiency of antibody design and production.
BioGlyph is led by CEO and co-founder Fernando Garces, who previously served as director of Protein Therapeutics at Gilead Sciences and principal scientist at Amgen. The company's founder McClain Kressman is currently pursuing a PhD at the University of California, Santa Cruz. Avi Peltz also serves as a co-founder and leads software development at BioGlyph.
Garces explains that after 20 years in protein engineering, he recognized the limitations of traditional tools in keeping up with the increasing complexities of biotherapeutics, especially MsAbs. This led the BioGlyph team to develop a visual software solution that empowers protein engineers with creativity while managing registration, data labeling, and in-silico testing of MsAbs' fitness, among other functions. He believes that their software will empower R&D scientists to make better decisions that accelerate timelines and lower costs.
More on Boston Chron
- Boston: Mayor Wu, Superintendent Skipper Cut Ribbon on Josiah Quincy Upper School
- National Policing Institute Honors Chief Kathleen M. O'Toole And Sheriff Jerry L. Clayton
- Diversified Industrial Acquisition Agreement, Plus Major Contract Award for Large Fleet Trucking Provider: MingZhu Logistics: Stock Symbol: YGMZ
- Messageware Z-Day Guard v1.5 Expands MDR Security to Azure, Exchange, and Windows Servers
- SmartBear Delivers Full-Stack Observability Insights for Developers
Kressman adds that working together with Dotmatics will help them bring this highly sought-after technology to market in an expedited manner. He also mentions their eagerness to harness the power of AI in life sciences and provide protein engineers with cutting-edge tools for the future.
However, it is important to note that this press release contains forward-looking statements and is intended for informational purposes only. It should not be relied upon for making purchase decisions as it does not guarantee any specific functionality or product release. The development, release, and timing of any products or capabilities remain at the sole discretion of Dotmatics.
Additionally, no representation or warranty is provided regarding the accuracy or reliability of the information expressed in this press release. Any legal effect will only be applicable if stated in one or more definitive agreements involving both parties.
Filed Under: Business
0 Comments
Latest on Boston Chron
- Boston Globe Media Launches B-Side Sports with Strategic Partnership alongside Shadow Lion
- Policy vs Politics Rebrands to Everything Policy: A New Era of Facts-first Policy Content
- GitKraken Launches DevEx Advance Partner Program to Help Atlassian Solution Partners Elevate Their Clients' Developer & DevOps Team Productivity
- Phinge's Plan to Save Free Speech and Give Everyone the Right to Personal Privacy and Ownership and Monetization of Their Online Data and Content
- The Royalty Network and CEO Frank Liwall Appoint Daniel Abowd as New President & General Counsel
- L2 Aviation Announces Strategic Growth Investment from Argentum
- African-American Marketing Association Launches Business of Marketing Bootcamp™ for Small Businesses
- WOHLER Announces its NEW iAM1-MIX8 Next Generation MIX Series Solution @ IBC 2024
- Inaugural Tough Tech Week in Boston Will Gather Inventors, Investors, and Innovators for Five Days of Collaboration and Connection
- The World's No.1 Superstar Dies After Choking on a French Fry
- Award-winning and Renowned Voice Actor Nancy Cartwright to Deliver Keynote at the That's Voiceover Career Expo 2024 in Los Angeles
- "Army of Liars" Exposes How Social Media Profits from Disinformation
- Cerity Partners Appoints Todd Cassler as First-Ever Chief Growth Officer
- Vantiva Demonstrates its Vision of the Connected Home of the Future with New Lineup of AI-Powered CPE at IBC 2024
- ApostilleDepot.com Expands Services to Offer Comprehensive Apostille & Document Legalization Solutions in Massachusetts and New Hampshire
- Challenge Arcade's World Record Weekend 2024
- Empowering Educators with AI: Goosechase and DIGITAL Partner for the Future of Interactive Experiences
- Join Us at the 136th Canton Fair from October 15th to 19th, 2024!
- Legendary Aviation Coffee Company Celebrates 2100% Growth with Exceptional Single-Origin Air-Roasted Coffee
- General Vincent Brooks (RET) Joins BEYA Stars and Stripes Committee as a Founder, Following 20 Years of Service by General Johnnie Wilson (RET)